Cadrenal Therapeutics (CVKD) highlighted the significant unmet medical need in heparin-induced thrombocytopenia and underscored the promise of its recently acquired investigational drug candidate, VLX-1005. Cadrenal Therapeutics acquired VLX-1005 in December 2025, recognizing its potential to transform the treatment landscape for HIT and other immune-mediated thrombotic disorders. Emerging data from a recent Phase 2 clinical trial evaluating VLX-1005 in individuals with suspected HIT suggest that VLX-1005 may reduce thrombotic complications, supporting its further development as a novel, mechanism-based therapy. Early trial results suggest that selective 12-LOX inhibition may offer a differentiated approach by addressing the immune thrombotic drivers of disease rather than solely suppressing coagulation.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVKD:
- Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity
- Cadrenal Therapeutics Announces New Securities Purchase Agreement
- Cadrenal Therapeutics Acquires VLX-1005 from Veralox
- Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia
- Cadrenal Therapeutics Appoints Dr. Golden to Board